HNI Corporation (HNI)

Verve Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts that cover Verve Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $66.5, which forecasts a 53.58% increase in the stock price over the next year. The lowest target is $63 and the highest is $70.

Price Target: $66.5 (+53.58%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$63	$66.5	$70	$70
Change	+45.50%	+53.58%	+61.66%	+61.66%

* Price targets were last updated on May 16, 2025.

Analyst Ratings

The average analyst rating for Verve Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	1	1	1	2	2	2
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Macgregor Longbow Research	Longbow Research	Strong Buy Initiates $70	Strong Buy	Initiates	$70	+61.66%	May 16, 2025
Reuben Garner Benchmark	Benchmark	Strong Buy Maintains $57 → $63	Strong Buy	Maintains	$57 → $63	+45.50%	Jul 26, 2024
Reuben Garner Benchmark	Benchmark	Strong Buy Maintains $54 → $57	Strong Buy	Maintains	$54 → $57	+31.64%	May 29, 2024
Reuben Garner Benchmark	Benchmark	Strong Buy Maintains $50 → $54	Strong Buy	Maintains	$50 → $54	+24.71%	Apr 30, 2024
Reuben Garner Benchmark	Benchmark	Strong Buy Maintains $36 → $45	Strong Buy	Maintains	$36 → $45	+3.93%	Aug 9, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

2.67B

Increased by 5.72%

from 2.53B

Revenue Next Year

2.77B

Increased by 3.63%

from 2.67B

EPS This Year

3.49

Increased by 21.06%

from 2.88

EPS Next Year

4.02

Increased by 15.35%

from 3.49

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Jan 2, 2021	Jan 1, 2022	Dec 31, 2022	Dec 30, 2023	Dec 28, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.96B	2.18B	2.36B	2.43B	2.53B	2.67B	2.77B	2.93B
Revenue Growth	-12.98%	11.71%	8.12%	3.06%	3.80%	5.72%	3.63%	5.74%
EPS	0.98	1.36	2.94	1.09	2.88	3.49	4.02	4.75
EPS Growth	-61.42%	38.78%	116.18%	-62.93%	164.22%	21.06%	15.35%	18.03%
Forward PE	-	-	-	-	-	12.42	10.77	9.12
No. Analysts	-	-	-	-	-	6	6	2

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	2.8B	3.0B	3.0B
Avg	2.7B	2.8B	2.9B
Low	2.6B	2.6B	2.8B

Revenue Growth

Revenue Growth	2025	2026	2027
High	10.4%	10.6%	9.9%
Avg	5.7%	3.6%	5.7%
Low	1.7%	-1.0%	2.6%

EPS Forecast

EPS	2025	2026	2027
High	3.78	4.52	4.94
Avg	3.49	4.02	4.75
Low	3.19	3.76	4.61

EPS Growth

EPS Growth	2025	2026	2027
High	31.3%	29.5%	22.7%
Avg	21.1%	15.4%	18.0%
Low	10.9%	7.9%	14.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.